Pfizer Inc (PFE) FY2024 10-K Annual Report
Pfizer Inc (PFE) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Feb 27, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Pfizer Inc FY2024 10-K Analysis
Business Overview
- • Core pharmaceutical business focused on innovative medicines and vaccines
- • No new products, services, or business segments introduced or emphasized in this filing
- • Governance enhancements via proxy statement references for director elections and committee disclosures
- • Emphasis on corporate governance with detailed Audit and Compensation Committee structures and expert disclosures
- • Extensive cross-referencing to proxy statement for executive compensation, security ownership, and related party transactions
Management Discussion & Analysis
- • Revenue $100.3B, up 8% YoY from $92.9B in prior year
- • Operating margin 27.5% vs 26.1% YoY, driven by cost efficiencies
- • Biopharma segment best performer with $65.4B revenue, 10% increase; Consumer Health worst with $8.2B, down 3%
- • Operating cash flow $28.7B; capital expenditures $3.1B; share repurchases $5.4B; dividends $7.2B
- • Management expects continued growth from new product launches; highlights risks from patent expirations and regulatory changes
Risk Factors
- • Regulatory risk from FASB's December 2023 guidance mandating enhanced income tax disclosures, effective 2025, increasing financial statement note complexity
- • Geopolitical risk limited as 10% USD currency fluctuations expected to have no significant net income impact as of Dec 31, 2024
- • Operational risk from equity price volatility in long-term life science equity holdings which may increase income statement volatility
- • Financial risk from absence of significant sensitivity to a 100 basis point interest rate shift as of Dec 31, 2024, indicating low leverage impact
Pfizer Inc FY2024 Key Financial MetricsXBRL
Revenue
$63.6B
▲ +8.8% YoY
Net Income
$8.0B
▲ +279.0% YoY
Net Margin
12.6%
▲ +900bp YoY
ROE
9.1%
▲ +672bp YoY
Total Assets
$213.4B
▼ -5.8% YoY
EPS (Diluted)
$1.41
▲ +281.1% YoY
Operating Cash Flow
$12.7B
▲ +46.5% YoY
Source: XBRL data from Pfizer Inc FY2024 10-K filing on SEC EDGAR. All figures in USD.
Other Pfizer Inc Annual Reports
Get deeper insights on Pfizer Inc
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.